Source comparison
Hexarelin vs CJC-1295 for GH Research UK 2026
All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, therapeutic application, or clinical treatment. This content is directed at qualified researchers operati
This comparison does not assign a generated winner or score.
- All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, therapeutic application, or clinical treatment. This content is directed at qualified researchers operating within applicable UK regulatory frameworks (Research Use Only).
- Hexarelin and CJC-1295 are both growth hormone (GH) secretagogues, but they operate through fundamentally distinct receptor systems and produce radically different pharmacological profiles — differences that make direct comparison essential for study design. Where CJC-1295 acts exclusively through the GHRH receptor (GHRHR) on pituitary somatotrophs, Hexarelin’s activity spans the GHS-R1a receptor, the CD36 scavenger receptor (GHS-R1a-independent), and — when used with the DAC (Drug Affinity Complex) modification — produces prolonged exposure kinetics. This post examines the head-to-head mechanistic landscape. It is distinct from the CJC-1295 vs Ipamorelin comparison (ID 77443, GHS-R1a selectivity versus GHRHR), the Ipamorelin vs Hexarelin comparison (ID 77402, intra-GHS-R1a selectivity), and the individual pillar guides for Hexarelin and CJC-1295.